Alterola Biotech, Inc. Reports Earnings Results for the Full Year Ended September 30, 2018
December 15, 2020 at 03:37 am IST
Share
Alterola Biotech, Inc. announced earnings results for the full year ended September 30, 2018. For the full year, the company announced operating loss was USD 122,557 compared to USD 49,132 a year ago. Net loss was USD 133,067 compared to USD 67,632 a year ago.
Alterola Biotech, Inc. is a pharmaceutical company. The Company is engaged in the development of cannabinoid, cannabinoid-like, and non-cannabinoid pharmaceutical active pharmaceutical ingredients (APIs); pharmaceutical medicines made from cannabinoid, cannabinoid-like, and non-cannabinoid APIs; and European food approval of cannabinoid-based, cannabinoid-like, and non-cannabinoid ingredients and products. The Company has three areas of focus: development of regulated pharmaceuticals (human and animal health) and regulated food products; production of APIs and food-grade ingredients; and formulation, and drug delivery, providing bioavailability, solubility, and stability. It also focuses on developing new medicines from various sources, including botanical, traditional chemical synthesis, and biosynthetic methodologies. Its wholly owned subsidiaries include ABTI Pharma Ltd, Phytotherapeutix Ltd, and Ferven Ltd.
ALTEROLA BIOTECH, INC. 
